Someone else's clock has started running against them: the company is being paid to solve a problem that is already cost
The model's full reasoning — Q1 2018 call → NOWe need to determine if management describes counterparts already losing something real and ongoing for as long as they don't have what the company provides, and that this is visible in their behavior. Also that this dynamic is generating meaningful business with contribution ahead. We need to find in the transcript whether they describe a running meter on the other side - some cost/loss/opportunity cost accumulating for customers or partners that only stops when they get the product. And also behavior reflecting that. Let's read the management statements. The call is about Illumina's Q1 2018 earnings. The company sells sequencing instruments and consumables, microarrays, etc. Customers include research labs, clinical labs, population genomics programs, etc. Look for descriptions of customers who are losing something because they don't have the product. There are mentions of demand, momentum, but is there a specific "running meter"? For example, in oncology, there might be patients waiting, but that's indirect. In consumer genomics, there is growth. One phrase: "It's an important reminder that while NovaSeq is a key enabler for some of our customers. The growth in sequencing demand more broadly is a key driver of our business." That doesn't describe a meter. Look for "customers are seeing mounting awareness and acceptance" - that is demand, not a meter. Maybe in population genomics: "The genomics England initiative, which is now halfway through its 100,000 genome target and hopes to complete sequencing all 100,000 genomes this year." That's not a meter. They mention customers transitioning from HiSeq to NovaSeq, and HiSeq consumables down. That is a transition, but not a loss. They mention "clinical oncology applications just announced with BMS and Loxo Oncology" - those are partnerships, not showing a running meter. They talk about the NIPT study with Harvard Pilgrim to demonstrate clinical and economic value. That is a future study. Do they describe a "running meter" such as "each quarter they delay, they lose market share" or "they are racing against their competitors"? Possibly there is something about "customers are racing their own competitors" - let's see. In the context of population genomics: "we continue to believe in the long-term elasticity of this market." Not a meter.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
SYM · Q3 2022 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...YES The transcript shows management describing customers' ongoing pain from labor shortages and broken supply chains that prevent them from handling demand, with customers actively clamoring for faster deployments and wanting the system as quickly as possible.
CRL · Q2 2022 → YESThe question is whether management describes that their counterparties are already losing something real and ongoing — money, output, access, standing, time, or an opportunity — for as long as they do...
GTES · Q4 2021 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...